Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACCUNEB vs BREO ELLIPTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors, increasing cyclic AMP, and inhibiting mediator release from mast cells.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Acute prophylaxis against exercise-induced bronchospasm
Maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema,Maintenance treatment of asthma in patients aged 18 years and older
Inhaled: Nebulized solution 0.63 mg or 1.25 mg three times daily every 6-8 hours; or 0.63 mg twice daily in patients with asthma. Alternatively, 2.5 mg three times daily via nebulization.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
2-5 hours (procainamide); 6-8 hours (N-acetylprocainamide); prolonged in renal impairment (up to 20 hours)
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Metabolized primarily by catechol-O-methyltransferase (COMT) and to a lesser extent by sulfatase enzymes in the gastrointestinal tract.
Fluticasone furoate: primarily metabolized by CYP3A4; Vilanterol: primarily metabolized by CYP3A4.
Renal: ~70% as unchanged drug and active metabolite (N-acetylprocainamide) within 24 hours; biliary/fecal: minimal (<5%)
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
15-20% bound to albumin and alpha-1-acid glycoprotein
Fluticasone furoate: >99.8% (primarily albumin). Vilanterol: approximately 94% (albumin and alpha-1-acid glycoprotein).
1.5-2.5 L/kg; distributes widely into tissues with high affinity for cardiac tissue
Fluticasone furoate: approximately 4.5 L/kg (extensive tissue distribution). Vilanterol: approximately 165 L (large Vd, extensive distribution).
Oral immediate-release: 75-95%; IM: 100%; IV: 100%
Inhaled: Fluticasone furoate absolute bioavailability approximately 15% (lung deposition). Vilanterol absolute bioavailability approximately 27% (lung deposition). Oral bioavailability is negligible for both (<2% for fluticasone furoate, <5% for vilanterol).
No specific dose adjustment required; drug undergoes minimal renal excretion. Use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential for systemic accumulation.
No dosage adjustment required for renal impairment. However, use with caution in severe renal impairment due to potential for increased systemic exposure.
No specific dose adjustment for Child-Pugh Class A or B. For Child-Pugh Class C, consider dose reduction by 50% due to reduced clearance.
Child-Pugh Class A and B: No dosage adjustment recommended. Child-Pugh Class C: Contraindicated.
Children 2-12 years: Nebulized solution 0.31 mg, 0.63 mg, or 1.25 mg three times daily every 6-8 hours based on severity. For children ≥12 years, same as adult dosing.
Indicated for children aged 5 years and older with asthma. For ages 5-11: one inhalation of 100 mcg/25 mcg once daily. For ages 12 and older: same as adult dosing.
Start at lower end of dosing range (0.63 mg three times daily) due to potential age-related renal impairment and increased sensitivity to beta-agonists. Monitor for tachycardia and tremors.
No dose adjustment required for elderly patients. Use with caution due to increased risk of comorbidities and adverse effects.
None
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Use only as additional therapy for patients not adequately controlled on a long-term asthma control medication or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
Paradoxical bronchospasm,Cardiovascular effects including increased heart rate and blood pressure,Hypokalemia,Immediate hypersensitivity reactions
Increased risk of asthma-related death when used as monotherapy for asthma without inhaled corticosteroid,Candida infections of the mouth and pharynx,Pneumonia in patients with COPD,Adrenal insufficiency,Hypercorticism and adrenal suppression,Paradoxical bronchospasm,Hypersensitivity reactions including anaphylaxis,Cardiovascular effects like increased blood pressure and heart rate,Eosinophilic conditions,Reduced bone mineral density,Glaucoma and cataracts
Hypersensitivity to levalbuterol or any component of the product
Status asthmaticus or acute episodes of COPD requiring intensive therapy,Primary treatment of acute asthma exacerbation,Severe hypersensitivity to milk proteins or any ingredient
No specific food interactions. Avoid caffeine and other stimulants as they may increase side effects like nervousness and rapid heartbeat.
No specific food interactions reported. However, grapefruit juice may increase systemic exposure to fluticasone furoate via CYP3A4 inhibition; although clinical significance is low, avoid excessive grapefruit consumption. No dietary restrictions necessary.
ACCUNEB (levalbuterol) is a beta-2 adrenergic agonist. Based on animal studies and human data, there is no evidence of teratogenicity. However, during the second and third trimesters, beta-agonists may cause fetal tachycardia, hypoglycemia, and hypocalcemia. Use only if potential benefit justifies risk.
Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at high systemic exposures. Avoid in first trimester unless benefit outweighs risk; use lowest effective dose in later trimesters.
Levalbuterol is excreted into breast milk in small amounts. The M/P ratio is unknown. Caution is advised; monitor infant for signs of beta-adrenergic stimulation (e.g., tachycardia, irritability).
No data on drug excretion in human milk; M/P ratio unknown. Corticosteroids and LABAs are expected to be present in low concentrations. Caution if breastfeeding, especially in preterm infants. Consider alternative therapies.
Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, clearance) may require dose adjustments. Titrate to clinical effect; monitor for bronchospasm and side effects. No specific dose adjustment guidelines are established; use lowest effective dose.
No specific dose adjustments required due to pregnancy-induced pharmacokinetic changes, but use lowest effective dose to maintain asthma control due to potential fetal risk.
ACCUNEB (levalbuterol) is the R-isomer of albuterol, designed to reduce beta-adrenergic side effects. It is preferred in patients with tachycardia or sensitivity to beta-agonists. Monitor for paradoxical bronchospasm; discontinue immediately if occurs. Nebulized solution should be used with a jet nebulizer connected to an air compressor. Not for acute deterioration unless patient is already on regular therapy.
Breo Ellipta (fluticasone furoate/vilanterol) is an ICS/LABA combination indicated for maintenance treatment of COPD and asthma. It is not for acute bronchospasm. The ELLIPTA inhaler is a once-daily, dry powder inhaler; each actuation delivers a fixed dose. Rinse mouth with water after use without swallowing to reduce oral candidiasis. Monitor for pneumonia in COPD patients. In asthma, it is not indicated for patients under 18 years; for COPD, use only in patients with a history of exacerbations. Do not discontinue abruptly.
Use only as prescribed; do not increase dose or frequency without consulting your doctor.,Shake the nebulizer solution well before use. Do not mix with other medications unless instructed.,If you experience worsening breathing, chest tightness, or hives, stop the medication and seek medical help immediately.,Rinse mouth with water after each use to prevent throat irritation and thrush.,Store at room temperature away from light and moisture. Do not freeze.
Use exactly as prescribed; it is not a rescue inhaler for sudden breathing problems.,Rinse mouth with water after each dose without swallowing to prevent oral thrush.,Do not stop taking this medication without consulting your doctor; stopping can worsen breathing.,Tell your doctor if you have any signs of infection, pneumonia, or worsening breathing.,Store the inhaler at room temperature away from moisture and heat; keep it closed when not in use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACCUNEB vs BREO ELLIPTA, answered by our medical review team.
ACCUNEB is a Beta-2 Agonist that works by Relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors, increasing cyclic AMP, and inhibiting mediator release from mast cells.. BREO ELLIPTA is a Corticosteroid/Beta-2 Agonist Combination that works by Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACCUNEB and BREO ELLIPTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACCUNEB is: Inhaled: Nebulized solution 0.63 mg or 1.25 mg three times daily every 6-8 hours; or 0.63 mg twice daily in patients with asthma. Alternatively, 2.5 mg three times daily via nebulization.. The standard adult dose of BREO ELLIPTA is: One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACCUNEB and BREO ELLIPTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACCUNEB is classified as Category C. ACCUNEB (levalbuterol) is a beta-2 adrenergic agonist. Based on animal studies and human data, there is no evidence of teratogenicity. However, during the second and third trimeste. BREO ELLIPTA is classified as Category C. Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.